Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

A recent survey conducted by the HIV Medicine Association identified barriers to implementation of long-acting injectables ...

It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

Three bovine veterinarians had undetected H5N1 avian influenza infections despite no apparent contact with infected cows, ...

The latest announcement follows the recent US Food and Drug Administration (FDA) acceptance of the company’s new drug ...

Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...

在这一革命性技术的背后，是一项令人惊艳的生物学突破。lenacapavir采用皮下植入式长效缓释的黑科技，能够在体内持续发挥作用，确保高危人群获得持久的保护。其三维抗病毒靶向机制的示意图展现了其对细胞的精准攻击，让病毒无处遁形。更令人振奋的是，在近期的临床试验中，南非高危人群的防护率高达99.7%，而性少数群体的用药依从性提升幅度也达到了惊人的300%。这意味着，lenacapavir不仅加强了预 ...

得益于抗逆转录病毒疗法的发展，HIV感染已经从致命疾病转变为可控的慢性病，患者只要每日坚持服药，就可获得与正常人相当的寿命。然而根据世界卫生组织（WHO）的统计，仅在2023年，全球仍有近4000万艾滋病患者，其中有130万新增感染，约63万人死于艾 ...

The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...